[HTML][HTML] Innate immunity and interferon in SARS-CoV-2 infection outcome
Innate immunity and the actions of type I and III interferons (IFNs) are essential for protection
from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to …
from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to …
[HTML][HTML] Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
M Buchynskyi, I Kamyshna, K Lyubomirskaya… - Frontiers in …, 2023 - frontiersin.org
Introduction IFN-α intervention may block SARS-CoV-2 replication and normalize the
deregulated innate immunity of COVID-19. Aim This meta-analysis aimed to investigate the …
deregulated innate immunity of COVID-19. Aim This meta-analysis aimed to investigate the …
[HTML][HTML] Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized …
Interferon (IFN) has been highlighted in several randomized controlled trials as an attractive
therapeutic candidate based plausible mode of action, suppressed response in severe …
therapeutic candidate based plausible mode of action, suppressed response in severe …
[HTML][HTML] Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection
D Fraser-Pitt, DK Mercer, ML Francis… - Biochemical and …, 2023 - Elsevier
Transient blockade of glycine decarboxylase (GLDC) can restrict de novo pyrimidine
synthesis, which is a well-described strategy for enhancing the host interferon response to …
synthesis, which is a well-described strategy for enhancing the host interferon response to …
Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19
D Ma, X Wang, M Li, C Hu, L Tang - International Immunopharmacology, 2023 - Elsevier
Periodic pandemics of coronavirus (CoV)–related pneumonia have been a major
challenging issue since the outbreak of severe acute respiratory syndrome (SARS) in 2002 …
challenging issue since the outbreak of severe acute respiratory syndrome (SARS) in 2002 …
[HTML][HTML] Antiviral therapy of COVID-19
G Gudima, I Kofiadi, I Shilovskiy, D Kudlay… - International Journal of …, 2023 - mdpi.com
Since the beginning of the COVID-19 pandemic, the scientific community has focused on
prophylactic vaccine development. In parallel, the experience of the pharmacotherapy of this …
prophylactic vaccine development. In parallel, the experience of the pharmacotherapy of this …
[HTML][HTML] The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients
Enzyme inhibitors are frequently used to treat viral illnesses. Protease inhibitors are a
promising class for combating novel and life-threatening viral infections. This research …
promising class for combating novel and life-threatening viral infections. This research …
[引用][C] La radioteràpia a dosis baixes: una alternativa terapèutica en pacients ancians amb pneumònia severa causada per COVID-19
B Piqué Smith - Universitat Rovira i Virgili